Rankings
▼
Calendar
LGND Q3 2020 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena
LGND
Ligand Pharmaceuticals Incorporated
$4B
Q3 2020 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$42M
+68.7% YoY
Gross Profit
$35M
84.8% margin
Operating Income
$4M
9.0% margin
Net Income
-$7M
-16.0% margin
EPS (Diluted)
$-0.42
QoQ Revenue Growth
+1.0%
Cash Flow
Operating Cash Flow
$13M
Free Cash Flow
$11M
Stock-Based Comp.
$8M
Balance Sheet
Total Assets
$1.2B
Total Liabilities
$550M
Stockholders' Equity
$698M
Cash & Equivalents
$457M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$42M
$25M
+68.7%
Gross Profit
$35M
$22M
+63.9%
Operating Income
$4M
-$5M
+172.6%
Net Income
-$7M
-$15M
+56.1%
Revenue Segments
Material Sales, Captisol
$23M
39%
Contract Revenue
$9M
16%
Royalty
$9M
15%
Contract Revenue, Service
$7M
12%
Kyprolis
$7M
11%
Evomela
$2M
3%
License Fees, Milestones, and Product, Other, Product, Other
$995,000
2%
Milestone
$960,000
2%
Royalty, Other
$280,000
0%
License Fees
$158,000
0%
← FY 2020
All Quarters
Q4 2020 →